Belgium· BE-AMP-SAM208293-00
Kabiven 14 GN
A lösungen zur parenteralen ernährung, kombinationen product containing sodium glycerophosphate hydrate, registered in Belgium by Fresenius Kabi. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lösungen zur parenteralen ernährung, kombinationen is registered in 11 of 19 countries.
Countries holding a registration under ATC B05BA10 (lösungen zur parenteralen ernährung, kombinationen), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Lösungen zur parenteralen ernährung, kombinationen · ATC B05BA10
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Sodium Glycerophosphate Hydrate
- Manufacturer
- Fresenius Kabi
- Country
- Belgium (BE)
- ATC code
- B05BA10
- ATC class
- Lösungen zur parenteralen Ernährung, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb0764886
- be_apb1573427EUR 28.75
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for lösungen zur parenteralen ernährung, kombinationen.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lösungen zur parenteralen ernährung, kombinationen · interactions on record
6 records
- 2 severe
- 4 moderate
Most severe, free to view
- ErdafitinibL01EN01severe
- ErdafitinibL01EX16severe
- AmfetamineN06BA01moderate
- DexamfetamineN06BA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lösungen zur parenteralen ernährung, kombinationen in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandGlycophosInPharm Sp. z o.o.
- United KingdomGlycophos 4.32g/20ml concentrate for solution for infusion vialsFresenius Kabi Ltd
- FinlandGlycophosFresenius Kabi AB
- CzechiaSODIUM GLYCEROPHOSPHATE FRESENIUSFresenius Kabi s.r.o., Praha
- GermanyNatriumglycerophosphat-Ampulle FreseniusFresenius Kabi Deutschland Gmbh
- FranceGLYCEROPHOSPHATE DE SODIUM KABI 216 mg/mL (1 mmol/mL), solution à diluer pour perfusionFRESENIUS KABI FRANCE
- NorwayGlycophosFresenius Kabi
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Glycophos
- Cyprus · Glycophos
- Czechia · Sodium Glycerophosphate Fresenius
- Germany · Natriumglycerophosphat-Ampulle Fresenius
- Denmark · Glycophos
- Spain · Glycophos
- Finland · Glycophos
- France · Glycerophosphate De Sodium
- Greece · Glycophos
- Hungary · Nátrium-Glicerin-Foszfát Fresenius
- Italy · Glycophos
- Lithuania · Glycophos
- Latvia · Glycophos
- Netherlands · Glycophos
- Poland · Glycophos
- Portugal · Glycophos
- Romania · Glycophos
- Sweden · Glycophos
- Slovakia · Sodium Glycerophosphate Fresenius
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af559b0b-221c-46c3-854c-06d687470adc GET /v1/drugs/af559b0b-221c-46c3-854c-06d687470adc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Emulsion for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Kabiven 14 GN",
"name_fr": "Kabiven 14 GN",
"name_nl": "Kabiven 14 GN",
"amp_code": "SAM208293-00",
"strengths": [
"1.4800",
"1.4800",
"2.5000",
"2.1400",
"1.5000",
"1.5000",
"1.6400",
"107.1700",
"97.4300",
"1.3300",
"2.5000",
"1.5000"
],
"pack_count": 4,
"substances": [
"Sodium Glycerophosphate Hydrate",
"Sodium Glycerophosphate",
"Sodium Acetate Trihydrate",
"Valine",
"Sodium Acetate",
"Methionine",
"Glucose Monohydrate",
"Glucose Anhydrous",
"Serine",
"Arginine",
"Glycine",
"Histidine",
"Magnesium Sulfate",
"Soya Oil",
"Threonine",
"Calcium Chloride Dihydrate",
"Calcium Chloride",
"Tyrosine",
"Proline",
"Leucine",
"Potassium Chloride",
"Isoleucine",
"Tryptophan",
"Phenylalanine",
"Alanine",
"Aspartic Acid",
"Lysine Hydrochloride",
"Lysine",
"Glutamic Acid",
"Glycerol",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Combinations",
"authorisation_numbers": [
"BE208293",
"BE340846"
]
}See everything about lösungen zur parenteralen ernährung, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.